Cargando…

Insight on Non-Coding RNAs from Biofluids in Ovarian Tumors

SIMPLE SUMMARY: Ovarian cancer is the most lethal gynecologic cancer since it is often diagnosed at advanced stages. Current tools for diagnosis are currently insufficient and include physical examination, ultrasound and pelvic magnetic resonance imaging, as well as algorithms combining thoraco-abdo...

Descripción completa

Detalles Bibliográficos
Autores principales: Dabi, Yohann, Favier, Amélia, Razakamanantsoa, Léo, Delbos, Léa, Poilblanc, Mathieu, Descamps, Philippe, Golfier, Francois, Touboul, Cyril, Bendifallah, Sofiane, Daraï, Emile
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001105/
https://www.ncbi.nlm.nih.gov/pubmed/36900328
http://dx.doi.org/10.3390/cancers15051539
_version_ 1784904052060979200
author Dabi, Yohann
Favier, Amélia
Razakamanantsoa, Léo
Delbos, Léa
Poilblanc, Mathieu
Descamps, Philippe
Golfier, Francois
Touboul, Cyril
Bendifallah, Sofiane
Daraï, Emile
author_facet Dabi, Yohann
Favier, Amélia
Razakamanantsoa, Léo
Delbos, Léa
Poilblanc, Mathieu
Descamps, Philippe
Golfier, Francois
Touboul, Cyril
Bendifallah, Sofiane
Daraï, Emile
author_sort Dabi, Yohann
collection PubMed
description SIMPLE SUMMARY: Ovarian cancer is the most lethal gynecologic cancer since it is often diagnosed at advanced stages. Current tools for diagnosis are currently insufficient and include physical examination, ultrasound and pelvic magnetic resonance imaging, as well as algorithms combining thoraco-abdomino-pelvic scans and blood markers. In this context, there is a need for new tools not only to assess the diagnosis but also to predict the response to chemotherapy and to detect recurrences. Previous studies have highlighted the potential value of non-coding RNAs (ncRNA) in tissue samples, but rarely in biofluids. In this review, we aim to summarize the existing literature on ncRNAs and ovarian tumors in biofluids. Most studies are focused on serum and blood with no data on other biofluids and with few ncRNAs investigated using qRT-PCR or microarray, which does not reflect the heterogeneity of ovarian cancers. ABSTRACT: Ovarian tumors are the most frequent adnexal mass, raising diagnostic and therapeutic issues linked to a large spectrum of tumors, with a continuum from benign to malignant. Thus far, none of the available diagnostic tools have proven efficient in deciding strategy, and no consensus exists on the best strategy between “single test”, “dual testing”, “sequential testing”, “multiple testing options” and “no testing”. In addition, there is a need for prognostic tools such as biological markers of recurrence and theragnostic tools to detect women not responding to chemotherapy in order to adapt therapies. Non-coding RNAs are classified as small or long based on their nucleotide count. Non-coding RNAs have multiple biological functions such as a role in tumorigenesis, gene regulation and genome protection. These ncRNAs emerge as new potential tools to differentiate benign from malignant tumors and to evaluate prognostic and theragnostic factors. In the specific setting of ovarian tumors, the goal of the present work is to offer an insight into the contribution of biofluid non-coding RNAs (ncRNA) expression.
format Online
Article
Text
id pubmed-10001105
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100011052023-03-11 Insight on Non-Coding RNAs from Biofluids in Ovarian Tumors Dabi, Yohann Favier, Amélia Razakamanantsoa, Léo Delbos, Léa Poilblanc, Mathieu Descamps, Philippe Golfier, Francois Touboul, Cyril Bendifallah, Sofiane Daraï, Emile Cancers (Basel) Review SIMPLE SUMMARY: Ovarian cancer is the most lethal gynecologic cancer since it is often diagnosed at advanced stages. Current tools for diagnosis are currently insufficient and include physical examination, ultrasound and pelvic magnetic resonance imaging, as well as algorithms combining thoraco-abdomino-pelvic scans and blood markers. In this context, there is a need for new tools not only to assess the diagnosis but also to predict the response to chemotherapy and to detect recurrences. Previous studies have highlighted the potential value of non-coding RNAs (ncRNA) in tissue samples, but rarely in biofluids. In this review, we aim to summarize the existing literature on ncRNAs and ovarian tumors in biofluids. Most studies are focused on serum and blood with no data on other biofluids and with few ncRNAs investigated using qRT-PCR or microarray, which does not reflect the heterogeneity of ovarian cancers. ABSTRACT: Ovarian tumors are the most frequent adnexal mass, raising diagnostic and therapeutic issues linked to a large spectrum of tumors, with a continuum from benign to malignant. Thus far, none of the available diagnostic tools have proven efficient in deciding strategy, and no consensus exists on the best strategy between “single test”, “dual testing”, “sequential testing”, “multiple testing options” and “no testing”. In addition, there is a need for prognostic tools such as biological markers of recurrence and theragnostic tools to detect women not responding to chemotherapy in order to adapt therapies. Non-coding RNAs are classified as small or long based on their nucleotide count. Non-coding RNAs have multiple biological functions such as a role in tumorigenesis, gene regulation and genome protection. These ncRNAs emerge as new potential tools to differentiate benign from malignant tumors and to evaluate prognostic and theragnostic factors. In the specific setting of ovarian tumors, the goal of the present work is to offer an insight into the contribution of biofluid non-coding RNAs (ncRNA) expression. MDPI 2023-02-28 /pmc/articles/PMC10001105/ /pubmed/36900328 http://dx.doi.org/10.3390/cancers15051539 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Dabi, Yohann
Favier, Amélia
Razakamanantsoa, Léo
Delbos, Léa
Poilblanc, Mathieu
Descamps, Philippe
Golfier, Francois
Touboul, Cyril
Bendifallah, Sofiane
Daraï, Emile
Insight on Non-Coding RNAs from Biofluids in Ovarian Tumors
title Insight on Non-Coding RNAs from Biofluids in Ovarian Tumors
title_full Insight on Non-Coding RNAs from Biofluids in Ovarian Tumors
title_fullStr Insight on Non-Coding RNAs from Biofluids in Ovarian Tumors
title_full_unstemmed Insight on Non-Coding RNAs from Biofluids in Ovarian Tumors
title_short Insight on Non-Coding RNAs from Biofluids in Ovarian Tumors
title_sort insight on non-coding rnas from biofluids in ovarian tumors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001105/
https://www.ncbi.nlm.nih.gov/pubmed/36900328
http://dx.doi.org/10.3390/cancers15051539
work_keys_str_mv AT dabiyohann insightonnoncodingrnasfrombiofluidsinovariantumors
AT favieramelia insightonnoncodingrnasfrombiofluidsinovariantumors
AT razakamanantsoaleo insightonnoncodingrnasfrombiofluidsinovariantumors
AT delboslea insightonnoncodingrnasfrombiofluidsinovariantumors
AT poilblancmathieu insightonnoncodingrnasfrombiofluidsinovariantumors
AT descampsphilippe insightonnoncodingrnasfrombiofluidsinovariantumors
AT golfierfrancois insightonnoncodingrnasfrombiofluidsinovariantumors
AT touboulcyril insightonnoncodingrnasfrombiofluidsinovariantumors
AT bendifallahsofiane insightonnoncodingrnasfrombiofluidsinovariantumors
AT daraiemile insightonnoncodingrnasfrombiofluidsinovariantumors